Moderna Reports Mixed Q4 Earnings, Stock Dips
Key Metrics:
* Revenue: $966 million (Q4), $3.2 billion (FY2024)
* EPS: Loss of $2.91 (Q4), Loss of $9.28 (FY2024)
Financial Performance:
Moderna's Q4 revenue exceeded Wall Street estimates, driven by sales of its COVID-19 vaccine, Spikevax. Despite strong revenue growth, the company missed on EPS due to higher expenses.
Company Outlook:
* Plans to reduce costs by 27% in 2024 compared to 2023
* Aiming to secure 10 product approvals by 2027 and enhance cost efficiencies
* Target to eliminate $1 billion in costs by end of 2025
Industry Factors:
Investors are monitoring Moderna's performance amidst declining demand for COVID-19 vaccines. The company is also facing potential challenges from the appointment of Robert F. Kennedy Jr. to lead the Department of Health and Human Services, who has criticized vaccine safety.
Analyst Commentary:
Analysts expect Moderna's earnings call to shed light on its 2025 guidance, implications of Kennedy's appointment, clinical milestones, and upcoming product launches.